{
  "eval_id": "S21",
  "eval_file": "evals/single/S21.json",
  "timestamp": "2025-09-18T17:14:17.301889+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy (sacituzumab govitecan) is indicated for adults with HR-positive, HER2-negative unresectable or metastatic breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. The main points are around use in later lines after progression, with efficacy and safety as described in the SmPC. For full details, please email me the SmPC or EPAR reference."
}